Abstract: Provided in the present disclosure is a method for sequencing a double-stranded target polynucleotide. The method can keep ATP at a relatively constant concentration during sequencing, so that the sequencing rate can be better kept stable and unchanged. Further provided in the present disclosure is a kit for sequencing a double-stranded target polynucleotide, the kit including a transmembrane pore in the membrane, a helicase, an ATP-generating enzyme and an ATP-generating substrate.

Abstract: A mutant and the uses thereof. Compared with the amino acid sequence shown in SEQ ID NO: 2, the mutant has at least one of the following mutation sites: the 24th, 26th, 27th, 29th, 30th, 31st, 32nd, 33rd, 36th, 37th, 40th, 66th, 79th, 84th, 88th, 102nd, 103rd, 104th, 110th, 123rd, 124th, 138th, 152nd, 163rd, 167th, 170th, 174th, 175th, 178th, 182nd and 183rd sites.

Abstract: A membrane forming device and a membrane forming method are provided. The membrane forming device includes: a base (10); a main body (20) arranged to the base (10) and the main body (20) having a recess; and an opening member (30) arranged inside a recess port on an end of the recess away from the base (10), and a hollow portion (32) of the opening member (30) being configured to form a amphipathic molecular membrane (80), wherein a cross-sectional area of the hollow portion (32) of the opening member (30) is smaller than that of the accommodating chamber (21).

Abstract: Provided is helicase BCH1X, which comprises an amino acid sequence represented by SEQ ID NO: 1 or 2. Further provided are a complex structure comprising helicase BCH1X and a binding moiety used for binding to a polynucleotide, and a use thereof in the control and characterization of a polynucleotide and in single molecule nanopore sequencing.

Abstract: The present invention provides a helicase BCH2X, comprising an amino acid sequence represented by any one of SEQ ID NOs: 1-3. The present invention also provides a complex structure comprising the helicase BCH2X and a binding moiety for binding polynucleotides. The present invention also provides a use of the helicase BCH2X or the complex structure comprising same in the control and characterization of polynucleotides and single-molecule nanopore sequencing.

Abstract: The present invention relates to the field of biotechnology, in particular to a DNA polymerase mutant and the use thereof. Compared with a wild type, the mutant provided in the present invention has a significantly improved DNA polymerization activity, significantly improved affinity to DNA and amplification uniformity; and has good effects in the amplification of multiplex PCR, high-GC templates and complex templates. A hot-start-version DNA polymerase is further prepared by means of using antibodies or chemical modifications, wherein the yield of the DNA polymerase is significantly improved, while the primer dimer is significantly decreased. The prepared mutant hot-start DNA polymerase can be applied to PCR amplification of multiplex PCR, high-GC templates and complex templates.

Abstract: Power converters including electronic-embedded transformers for current sharing and load-independent voltage gain are described. An example power converter system includes an input, an output, a power converter between the input and output, and a controller. The converter includes a first bridge, a second bridge, and an electronic-embedded transformer between the first and second bridge. The electronic-embedded transformer includes a bidirectional coupling switch bridge. The controller generates drive control signals for quasi-trapezoidal current modulation control of the bidirectional coupling switch bridge. The controller is configured to generate the drive control signals based on a commutation coefficient k and a switching frequency for the power converter. The commutation coefficient k can be set based on an inductance in the electronic-embedded transformer, a capacitance in the bidirectional coupling switch bridge, and a margin for resonant current commutation.

Abstract: Power converters including electronic-embedded transformers for current sharing and load-independent voltage gain are described. An example power converter system includes an input, an output, a power converter between the input and output, and a controller. The converter includes a first bridge, a second bridge, and an electronic-embedded transformer (EET) between the first and second bridge. The EET includes a capacitor and a capacitance coupling switch bridge. The controller generates phasing drive control signals for trapezoidal current modulation control of the capacitance coupling switch bridge of the EET. The controller is configured to generate the phasing drive control signals based on a phase shift coefficient, k, to set a duty cycle of a voltage from the capacitance coupling switch bridge. The controller is also configured to vary k from between 0 to 0.5 based on a load applied to the power converter system or other operating aspects of the power converter.

Abstract: The present application provides a detection chip assembly tool, a liquid injection apparatus and method, an electronic device, and a medium. The tool is mounted on a vacuumizing assembly, and comprises: a base mounted on a detection chip. The base is provided with a reaction cavity covering the detection chip and a fluid channel communicated with the reaction cavity, and is further provided with a liquid inlet groove structure communicated with the fluid channel and having a buffer solution injected. When the detection chip is filled with the buffer solution, the vacuumizing assembly is started to discharge air in the detection chip assembly tool, in response to the vacuumizing assembly vacuumizing, pressure relief is performed, and the buffer solution in the liquid inlet groove structure flows into the reaction cavity along the fluid channel under the action of negative pressure so as to fill the detection chip.

Abstract: A microfluidic device and a microfluid detection device, comprising a body (100) and a liquid channel (201) provided within the body (100); a fluid input port (103) communicated with the liquid channel (201) is also provided on the body (100), and an arrangement position of the fluid input port (103) does not include a sensing area (301). The microfluidic device and the microfluidic detection device are easy to operate, and can effectively solve the problem of introducing bubbles due to directly opening a liquid injection hole on the sensing area (301).

Abstract: Provided is a recombinant KOD polymerase, which is the following A) or B): the polymerase shown in A) is a protein having DNA polymerase activity that is obtained by modifying amino acid residues in at least one of the following 18 positions in a wild-type KOD DNA polymerase amino acid sequence: 675th, 385th, 710th, 674th, 735th, 736th, 606th, 709th, 347th, 349th, 590th, 676th, 389th, 589th, 680th, 384th, 496th and 383rd; the polymerase described by B) is a protein having DNA polymerase activity that is derived from A) by adding a tag sequence to an end of the amino acid sequence of the protein shown in A).

Abstract: Provided are a thermostable B-family DNA polymerase mutant and an application thereof. The thermostable B-family DNA polymerase mutant is provided to mutate amino acid residues in at least two of three sites of group A, i.e., 408, 409, and 410 in an amino acid sequence of thermostable B-family DNA polymerases to obtain proteins having DNA polymerase activity. A-group sites (408/409/410), B-group sites (451/485), C-group sites (389/383/384), D-group sites (589/67/680), E-group sites (491/493/494/497), and F-group sites (474/478/486/480/484) of several B-family DNA polymerases are analyzed to design the mutant.

Abstract: Provided is a recombinant KOD polymerase. A KOD polymerase mutant is a protein as follows: the protein is a protein having DNA polymerase activity that is obtained by modifying amino acid residues in at least one of the following 48 positions in the amino acid sequence of KOD DNA polymerase GH78: 267, 326, 347, 349, 353, 375, 378, 379, 380, 385, 451, 452, 453, 454, 457, 461, 465, 470, 474, 477, 478, 479, 480, 482, 484, 485, 486, 493, 496, 497, 514, 574, 584, 605, 610, 630, 665, 666, 667, 674, 676, 680, 682, 698, 707, 718, 723 and 729, without changing other amino acid sequences; and compared with KOD DNA polymerase GH78, with regard to catalysis, the recombinant DNA polymerase exhibits a faster reaction rate, better catalytic efficiency, better affinity and other advantages, thereby improving the reaction rate of DNA polymerase in sequencing and increasing the reaction read length.

Abstract: A chimeric DNA polymerase includes: a first fragment having at least 80% homology to at least part of an N-end domain of KOD DNA polymerase; a second fragment having at least 80% homology to at least part of an exonucleolytic domain of Pab DNA polymerase; a third fragment having at least 80% homology to at least part of the N-end domain of KOD DNA polymerase; a fourth fragment having at least 80% homology to at least part of a palm domain of Pfu DNA polymerase; a fifth fragment having at least 80% homology to at least part of a finger domain of Pab DNA polymerase; a sixth fragment having at least 80% homology to at least part of the palm domain of Pfu DNA polymerase; and a seventh fragment having at least 80% homology to at least part of a thumb domain of KOD DNA polymerase.

Abstract: Provided are a Phi29 DNA polymerase mutant with improved thermal stability and an use thereof in sequencing. The phi29 DNA polymerase mutant is represented by A) or B) below: the DNA polymerase mutant represented by the A) is a protein having DNA polymerase activity that is obtained by modifying at least one amino acid residue(s) in the following six sites in a phi29 DNA polymerase amino acid sequence: the 97-th, 123-th, 217-th, 224-th, 515-th, and 474-th sites; the DNA polymerase mutant represented by the B) is a protein having DNA polymerase activity that is derived from the A) by adding a tag sequence to a terminal of the amino acid sequence of the protein represented by the A).

Abstract: The present disclosure relates to a reverse transcriptase and an application thereof. The reverse transcriptase has mutation sites such as R450H compared with the wild-type M-MLV reverse transcriptase. The reverse transcriptase has increased polymerase activity, improved thermal stability, and reduced RNase H activity.

Abstract: Provided is a recombinant KOD polymerase, which is the following A) or B): the polymerase shown in A) is a protein having DNA polymerase activity that is obtained by modifying amino acid residues in at least one of the following 18 positions in a wild-type KOD DNA polymerase amino acid sequence: 675th, 385th, 710th, 674th, 735th, 736th, 606th, 709th, 347th, 349th, 590th, 676th, 389th, 589th, 680th, 384th, 496th and 383rd; the polymerase described by B) is a protein having DNA polymerase activity that is derived from A) by adding a tag sequence to an end of the amino acid sequence of the protein shown in A).

Abstract: Provided are a group of phi29 DNA polymerase mutants having increased thermal stability and use thereof. The phi29 DNA polymerase mutants are proteins obtained by performing point mutation A and/or point mutation B and/or point mutation C on phi29 DNA polymerase, the point mutation A meaning that an amino acid residue M at position 97 of the phi29 DNA polymerase is mutated to other amino acid residue, the point mutation B meaning that an amino acid residue L at position 123 of the phi29 DNA polymerase is mutated into other amino acid residue, and the point mutation C meaning that an amino acid residue E at position 515 of the phi29 DNA polymerase is mutated to other amino acid residue. The stability of the phi29 DNA polymerase mutants is higher than that of a wild-type phi29 DNA polymerase.

Abstract: Provided are a phi29 DNA polymerase mutant with increased thermo stability, a method for preparing the mutant, the use of the mutant, and a method for increasing the stability of the phi29 DNA polymerase.

Abstract: Provided are a phi29 DNA polymerase and an encoding gene and an application thereof. The phi29 DNA polymerase is C1) or C2): C1) is a protein with DNA polymerase activity obtained by substituting at least one of the 58th, 61st, 94th, 96th, 119th, and 155th amino acid residues in the amino acid sequence of a wild type phi29 DNA polymerase as shown in SEQ ID NO: 2 in the sequence listing; and C2) is a fusion protein obtained by linking a label to the N-terminus and/or C-terminus of the protein represented by C1). A 3?-5?exonuclease of the phi29 DNA polymerase has activity lower than that of the wild type phi29 DNA polymerase, and can efficiently and continuously synthesize DNA during amplification and sequencing.